-
1
-
-
77952606821
-
Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome: Etiology and emerging therapies
-
Clark AS, Vahdat LT: Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome: Etiology and emerging therapies. Support Cancer Ther 1:213-218, 2004
-
(2004)
Support Cancer Ther
, vol.1
, pp. 213-218
-
-
Clark, A.S.1
Vahdat, L.T.2
-
2
-
-
0035476911
-
Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients
-
DOI 10.1002/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A
-
Blum JL, Dieras V, Lo Russo PM, et al: Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92:1759-1768, 2001 (Pubitemid 32952493)
-
(2001)
Cancer
, vol.92
, Issue.7
, pp. 1759-1768
-
-
Blum, J.L.1
Dieras, V.2
Russo, P.M.L.3
Horton, J.4
Rutman, O.5
Buzdar, A.6
Osterwalder, B.7
-
3
-
-
10744229320
-
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- And taxane-pretreated metastatic breast cancer
-
DOI 10.1016/j.ejca.2003.11.007
-
Fumoleau P, Largillier R, Clippe C, et al: Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 40:536-542, 2004 (Pubitemid 38220770)
-
(2004)
European Journal of Cancer
, vol.40
, Issue.4
, pp. 536-542
-
-
Fumoleau, P.1
Largillier, R.2
Clippe, C.3
Dieras, V.4
Orfeuvre, H.5
Lesimple, T.6
Culine, S.7
Audhuy, B.8
Serin, D.9
Cure, H.10
Vuillemin, E.11
Morere, J.-F.12
Montestruc, F.13
Mouri, Z.14
Namer, M.15
-
4
-
-
0034778024
-
Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer
-
DOI 10.1023/A:1012281104865
-
Oshaughnessy JA, Blum J, Moiseyenko V, et al: Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 12:1247-1254, 2001 (Pubitemid 32994752)
-
(2001)
Annals of Oncology
, vol.12
, Issue.9
, pp. 1247-1254
-
-
O'Shaughnessy, J.A.1
Blum, J.2
Moiseyenko, V.3
Jones, S.E.4
Miles, D.5
Bell, D.6
Rosso, R.7
Mauriac, L.8
Osterwalder, B.9
Burger, H.-U.10
Laws, S.11
-
5
-
-
0041508753
-
Multicenter phase II study of oral capecitabine (Xeloda'') in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy
-
DOI 10.1093/annonc/mdg346
-
Reichardt P, Von Minckwitz G, Thuss-Patience PC, et al: Multicenter phase II study of oral capecitabine (Xeloda('')) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 14:1227-1233, 2003 (Pubitemid 37039048)
-
(2003)
Annals of Oncology
, vol.14
, Issue.8
, pp. 1227-1233
-
-
Reichardt, P.1
Von, M.G.2
Thuss-Patience, P.C.3
Jonat, W.4
Kolbl, H.5
Janicke, F.6
Kieback, D.G.7
Kuhn, W.8
Schindler, A.E.9
Mohrmann, S.10
Kaufmann, M.11
Luck, H.J.12
-
6
-
-
20044364346
-
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
-
DOI 10.1200/JCO.2005.05.098
-
Miller KD, Chap LI, Holmes FA, et al: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792-799, 2005 (Pubitemid 46224178)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.4
, pp. 792-799
-
-
Miller, K.D.1
Chap, L.I.2
Holmes, F.A.3
Cobleigh, M.A.4
Marcom, P.K.5
Fehrenbacher, L.6
Dickler, M.7
Overmoyer, B.A.8
Reimann, J.D.9
Sing, A.P.10
Langmuir, V.11
Rugo, H.S.12
-
7
-
-
33847722573
-
Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: A planned safety analysis in 1,864 patients
-
DOI 10.1200/JCO.2006.08.1075
-
Schmoll HJ, Cartwright T, Tabernero J, et al: Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: A planned safety analysis in 1,864 patients. J Clin Oncol 25:102-109, 2007 (Pubitemid 350003057)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.1
, pp. 102-109
-
-
Schmoll, H.-J.1
Cartwright, T.2
Tabernero, J.3
Nowacki, M.P.4
Figer, A.5
Maroun, J.6
Price, T.7
Lim, R.8
Van, C.E.9
Park, Y.-S.10
McKendrick, J.11
Topham, C.12
Soler-Gonzalez, G.13
De, B.F.14
Hill, M.15
Sirzen, F.16
Haller, D.G.17
-
8
-
-
4244063621
-
Use of "Bag Balm" as topical treatment of palmer-plantar erythrodysesthsia syndrome (PPES) in patients receiving selected chemotherapeutic agents
-
suppl; abstr 1632
-
Chin SF, Tchen N, Oza AM, et al: Use of "Bag Balm" as topical treatment of palmer-plantar erythrodysesthsia syndrome (PPES) in patients receiving selected chemotherapeutic agents. Proc Am Soc Clin Oncol 20:409a, 2001 (suppl; abstr 1632)
-
(2001)
Proc Am Soc Clin Oncol
, vol.20
-
-
Chin, S.F.1
Tchen, N.2
Oza, A.M.3
-
9
-
-
0032802955
-
Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia
-
DOI 10.1007/s002800050981
-
Lopez AM, Wallace L, Dorr RT, et al: Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol 44:303-306, 1999 (Pubitemid 29402199)
-
(1999)
Cancer Chemotherapy and Pharmacology
, vol.44
, Issue.4
, pp. 303-306
-
-
Lopez, A.M.1
Wallace, L.2
Dorr, R.T.3
Koff, M.4
Hersh, E.M.5
Alberts, D.S.6
-
10
-
-
0034231616
-
Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome: Incidence, recognition and management
-
Nagore E, Insa A, Sanmartín O: Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome: Incidence, recognition and management. Am J Clin Dermatol 1:225-234, 2000
-
(2000)
Am J Clin Dermatol
, vol.1
, pp. 225-234
-
-
Nagore, E.1
Insa, A.2
Sanmartín, O.3
-
11
-
-
0002640816
-
Capecitabine (Xeloda) in 162 patients with paclitaxel-pretreated MBC: Updated results and analysis of dose modifications
-
abstr 693
-
Blum J, Jones S, Buzdar A, et al: Capecitabine (Xeloda) in 162 patients with paclitaxel-pretreated MBC: Updated results and analysis of dose modifications. Eur J Cancer 37, 2001 (abstr 693)
-
(2001)
Eur J Cancer
, vol.37
-
-
Blum, J.1
Jones, S.2
Buzdar, A.3
-
12
-
-
0036235128
-
First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin
-
DOI 10.1093/annonc/mdf089
-
Cassidy J, Twelves C, Van Cutsem E, et al: First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13:566-575, 2002 (Pubitemid 34461140)
-
(2002)
Annals of Oncology
, vol.13
, Issue.4
, pp. 566-575
-
-
Cassidy, J.1
Twelves, C.2
Van, C.E.3
Hoff, P.4
Bajetta, E.5
Boyer, M.6
Rugat, R.7
Burger, U.8
Garin, A.9
Graeven, U.10
McKendrick, J.11
Maroun, J.12
Marshall, J.13
Osterwalder, B.14
Perez-Manga, G.15
Rosso, R.16
Rougier, P.17
Schilsky, R.L.18
-
13
-
-
77958110977
-
Novel and effective management of capecitabine induced hand foot syndrome
-
Batra Cancer Center: suppl; abstr 8105
-
Pendharkar D, Goyal H, Batra Cancer Center: Novel and effective management of capecitabine induced hand foot syndrome. J Clin Oncol 22:751, 2004 (suppl; abstr 8105)
-
(2004)
J Clin Oncol
, vol.22
, pp. 751
-
-
Pendharkar, D.1
Goyal, H.2
-
14
-
-
0036094628
-
Clinical evaluation of 40% urea and 12% ammonium lactate in the treatment of xerosis
-
Ademola J, Frazier C, Kim SJ, et al: Clinical evaluation of 40% urea and 12% ammonium lactate in the treatment of xerosis. Am J Clin Dermatol 3:217-222, 2002 (Pubitemid 34533780)
-
(2002)
American Journal of Clinical Dermatology
, vol.3
, Issue.3
, pp. 217-222
-
-
Ademola, J.1
Frazier, C.2
Kim, S.J.3
Theaux, C.4
Saudez, X.5
-
16
-
-
0016119633
-
Control of keratinization with alpha-hydroxy acids and related compounds: I. Topical treatment of ichthyotic disorders
-
Van Scott EJ, Yu RJ: Control of keratinization with alpha-hydroxy acids and related compounds: I. Topical treatment of ichthyotic disorders. Arch Dermatol 110:586-590, 1974
-
(1974)
Arch Dermatol
, vol.110
, pp. 586-590
-
-
Van Scott, E.J.1
Yu, R.J.2
-
17
-
-
0024511939
-
Alpha hydroxy acids: Procedures for use in clinical practice
-
Van Scott EJ, Yu RJ: Alpha hydroxy acids: Procedures for use in clinical practice. Cutis 43:222-228, 1989 (Pubitemid 19088743)
-
(1989)
Cutis
, vol.43
, Issue.3
, pp. 222-228
-
-
Van, S.E.J.1
Yu, R.J.2
-
18
-
-
44949195004
-
Candidate mechanisms for capecitabine-related hand-foot syndrome
-
DOI 10.1111/j.1365-2125.2008.03159.x
-
Milano G, Etienne-Grimaldi MC, Mari M, et al: Candidate mechanisms for capecitabine-related hand-foot syndrome. Br J Clin Pharmacol 66:88-95, 2008 (Pubitemid 351822156)
-
(2008)
British Journal of Clinical Pharmacology
, vol.66
, Issue.1
, pp. 88-95
-
-
Milano, G.1
Etienne-Grimaldi, M.-C.2
Mari, M.3
Lassalle, S.4
Formento, J.-L.5
Francoual, M.6
Lacour, J.-P.7
Hofman, P.8
-
19
-
-
0033778443
-
Chemotherapy-induced acral erythema: Report of a case and immunohistochemical findings
-
Tsuruta D, Mochida K, Hamada T, et al: Chemotherapy-induced acral erythema: Report of a case and immunohistochemical findings. Clin Exp Dermatol 25:386-388, 2000
-
(2000)
Clin Exp Dermatol
, vol.25
, pp. 386-388
-
-
Tsuruta, D.1
Mochida, K.2
Hamada, T.3
-
20
-
-
0016799829
-
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial
-
Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1975
-
(1975)
Biometrics
, vol.31
, pp. 103-115
-
-
Pocock, S.J.1
Simon, R.2
-
21
-
-
41949099104
-
Pyridoxine is not effective for the prevention of hand foot syndrome (HFS) associated with capecitabine therapy: Results of a randomized double-blind placebo-controlled study
-
suppl; abstr 9007
-
Lee S, Lee S, Chun Y, et al: Pyridoxine is not effective for the prevention of hand foot syndrome (HFS) associated with capecitabine therapy: Results of a randomized double-blind placebo-controlled study. J Clin Oncol 25:494s, 2007 (suppl; abstr 9007)
-
(2007)
J Clin Oncol
, vol.25
-
-
Lee, S.1
Lee, S.2
Chun, Y.3
-
22
-
-
0035576115
-
Methodologic lessons learned from hot flash studies
-
Sloan JA, Loprinzi CL, Novotny PJ, et al: Methodologic lessons learned from hot flash studies. J Clin Oncol 19:4280-4290, 2001 (Pubitemid 33096775)
-
(2001)
Journal of Clinical Oncology
, vol.19
, Issue.23
, pp. 4280-4290
-
-
Sloan, J.A.1
Loprinzi, C.L.2
Novotny, P.J.3
Barton, D.L.4
Lavasseur, B.I.5
Windschitl, H.6
-
23
-
-
0036174497
-
Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: A single-institution experience
-
DOI 10.1081/CNV-120000360
-
Abushullaih S, Saad ED, Munsell M, et al: Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: A single-institution experience. Cancer Invest 20:3-10, 2002 (Pubitemid 34151055)
-
(2002)
Cancer Investigation
, vol.20
, Issue.1
, pp. 3-10
-
-
Abushullaih, S.1
Saad, E.D.2
Munsell, M.3
Hoff, P.M.4
-
24
-
-
5644269852
-
Coming to grips with hand-foot syndrome: Insights from clinical trials evaluating capecitabine
-
(Williston Park) discussion 1173-1176, 1181-1184
-
Scheithauer W, Blum J: Coming to grips with hand-foot syndrome: Insights from clinical trials evaluating capecitabine. Oncology (Williston Park) 18:1161-1168, 2004; discussion 1173-1176, 1181-1184
-
(2004)
Oncology
, vol.18
, pp. 1161-1168
-
-
Scheithauer, W.1
Blum, J.2
-
25
-
-
77649213517
-
Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors
-
Wood L, Lemont H, Jatoi A, et al: Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors. Community Oncol 7:23-29, 2010
-
(2010)
Community Oncol
, vol.7
, pp. 23-29
-
-
Wood, L.1
Lemont, H.2
Jatoi, A.3
-
26
-
-
79951912547
-
-
Bayer HealthCare, AG, D-51368, Leverkusen, Germany
-
Tate L, Laferriere N, Lentini G, et al: 12414, A Phase III randomized, double-blind, placebo-controlled study of sorafenib as adjuvant treatment for hepatocellular carcinoma after surgical resection or local ablation. Bayer HealthCare, AG, D-51368, Leverkusen, Germany, 2008
-
(2008)
12414, A Phase III Randomized, Double-blind, Placebo-controlled Study of Sorafenib As Adjuvant Treatment for Hepatocellular Carcinoma after Surgical Resection or Local Ablation
-
-
Tate, L.1
Laferriere, N.2
Lentini, G.3
-
28
-
-
79951901956
-
-
GlaxoSmithKline, North Central Cancer Treatment Group (NCCTG), Breast International Group (BIG)
-
Perez E: N063D/BIG 2-06, ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study - A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer. GlaxoSmithKline, North Central Cancer Treatment Group (NCCTG), Breast International Group (BIG), 2008
-
(2008)
N063D/BIG 2-06, ALTTO: Adjuvant Lapatinib And/or Trastuzumab Treatment Optimisation Study - A Randomised, Multi-centre, Open-label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer
-
-
Perez, E.1
|